Iovance Biotherapeutics Inc is a pioneering biotech firm focused on developing innovative cell therapies for cancer treatment. Specializing in autologous tumor infiltrating lymphocyte technology, it offers solutions like Amtagvi for metastatic melanoma and Proleukin for renal cell carcinoma. The company is also advancing treatments for various cancers, including lung and gynecological cancers, through strategic partnerships with leading research institutions and biopharmaceutical companies. Originally Lion Biotechnologies, it rebranded to Iovance in 2017 and operates from San Carlos, California.
A relative unknown, if you don’t watch the biotherapeutics industry, Iovance Biotherapeutics (NASDAQ:IOVA | IOVA Price Prediction) surged 43% in the past week after reporting Q4 2025 earnings on February 24, pushing…
David Beren Public offerings of stock tempted some insider buying, and one insider stepped up to support a struggling online delivery service provider.
One of Cathie Wood's ARK Invest funds sold over 300,000 shares of cancer-focused biopharma startup Iovance Bio on August 26.
One of Cathie Wood's ARK Invest funds bought over 125,000 shares of Iovance Bio on August 25.
A couple of Cathie Wood's Ark Invest funds bought over 1 million shares of Iovance Bio on May 20.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Thursday, including LendingTree, Merck, Micron Technology, Nvidia and Target.
These 10 stocks have incredibly strong stock charts and strong performance despite the crummy market conditions that have been seen so far in 2020.
